| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | 71,064 | 71,608 |
| Stock-based compensation expense | 8,350 | 5,579 |
| Impairment of intangible assets | 58,710 | 58,710 |
| Inventory obsolescence charge | 11,681 | 11,681 |
| Income tax expense | 2,948 | 3,381 |
| Depreciation and amortization expense | 3,692 | 3,300 |
| Non-cash interest expense | 2,037 | 1,352 |
| Fair value adjustment related to warrant and cvr liability | 1,379 | -4,127 |
| Accretion on investments | 2,271 | 1,060 |
| Fair value adjustment related to investments | -119 | 5 |
| Consulting fees paid in common stock | 75 | 75 |
| Loss on foreign currency exchange rates | -126 | -131 |
| Gain on sale of prv | 148,325 | 148,325 |
| Accounts and other receivables | 5,610 | 6,969 |
| Prepaid expenses and other current assets | 3,342 | 296 |
| Inventories | 780 | 586 |
| Operating lease right-of-use assets | -476 | 798 |
| Accounts payable and accrued expenses | -15,999 | -11,269 |
| Discount and rebate liabilities | 4,517 | 3,048 |
| Operating lease liabilities | -546 | 746 |
| Other liabilities | 4,823 | 1,991 |
| Net cash used in operating activities | -7,114 | -11,823 |
| Purchases of property and equipment | 866 | 312 |
| Disposals of property and equipment | 589 | - |
| Purchases of investments | 222,823 | 157,712 |
| Maturities of investments | 91,000 | 30,500 |
| Proceeds from sale of prv | 150,000 | 150,000 |
| Net cash provided by (used in) investing activities | 17,900 | 22,476 |
| Proceeds from issuance of debt, net of lender fees | 0 | 0 |
| Payment of third-party debt issuance costs | 0 | 0 |
| Repayment of debt | 0 | 0 |
| Proceeds from issuance of common stock for options exercised | - | 2,947 |
| Proceeds from insurance financing arrangements | 0 | 0 |
| Proceeds from employee stock purchase plan | 413 | 413 |
| Proceeds from issuance of stock | 0 | - |
| Proceeds from issuance of common stock for options exercised or rsus vested | 3,520 | - |
| Proceeds from issuance of common stock for warrants exercised | 5,957 | - |
| Payments of principal on insurance financing arrangements | 372 | 372 |
| Net cash provided by financing activities | 9,518 | 2,988 |
| Effect of exchange rate changes on cash and cash equivalents | 350 | 286 |
| Net increase in cash and cash equivalents | 20,654 | 13,927 |
| Cash and cash equivalents at beginning of period | 33,785 | - |
| Cash and cash equivalents at end of period | 54,439 | - |
ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC. (ZVRA)